STAT+: Dark money group runs ads on China biotech bill
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
Category: STAT+
STAT+: Pharmalittle: We’re reading about the Cencora data breach, a failed pandemic treaty, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite —…
STAT+: Airway disease drug from Insmed succeeds in one of the year’s most anticipated trials
An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway…
STAT+: Merus drug, with immunotherapy, boosts tumor response in patients with head and neck cancer
Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor…
STAT+: Japanese conglomerate to buy Calliditas Therapeutics, maker of a kidney disease drug
LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is…
STAT+: Gene therapies for deafness dredge up an old question: Do deaf people want a ‘cure’?
When Yilai Shu was training to be an otolaryngologist in Shanghai, in the mid 2000s,…
STAT+: Duchenne muscular dystrophy drug from Nippon Shinyaku fails in rare confirmatory trial
Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part…
STAT+: ASCO preview: a promising solid tumor CAR-T, an AI patient navigator, and improving palliative care
Thousands of cancer researchers and clinicians are flocking to Chicago for the American Society of…
STAT+: Nursing homes sue over Biden administration’s minimum staffing rule
A new federal lawsuit challenging the Biden administration’s new minimum nursing home staffing rule lays…
STAT+: Pharmalittle: We’re watching more positive data for Ozempic, a Lilly factory expansion, and more
It’s an honor to fill in for Ed Silverman this morning. There is only one…
STAT+: Ozempic cut risk of death in diabetes patients with chronic kidney disease
Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type…
STAT+: After MDMA therapy, she considered suicide. The trial data tell a different story
The MDMA study was her last hope. She had read headlines celebrating a 83% response…
Opinion: STAT+: Unmasking the ‘centricity’ illusion in clinical trials
During my 25 years working in clinical trial operations, I’ve seen the biopharmaceutical world talk…
STAT+: FDA advisers endorse Guardant Health’s colon cancer screening test
An independent panel of advisers to the Food and Drug Administration recommended the agency approve…
STAT+: Ahead of ASCO, J&J reports mixed data on next-generation radiopharmaceutical
An early-stage clinical trial of a radiopharmaceutical drug developed by Johnson & Johnson showed some…
STAT+: Pharma’s losing bet in New Jersey
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Pharmalittle: We’re watching a Cytokinetics deal with Royalty Pharma, Cue Health shutting down, and more
Top of the morning to you. I’m filling in for Ed Silverman this morning, which…
STAT+: Setting the table: What to expect at this year’s ASCO meeting
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again, and other thoughts
Thoughts about Cytokinetics after Wednesday night’s financing announcement: 1. Management is raising $500 million at…
STAT+: Biotechs turn to gene silencing for obesity drugs that can last longer than Wegovy
Enticed by the immense market opened by GLP-1 weight loss drugs Wegovy and Zepbound, a…
STAT+: Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575 million, lowering hopes of a buyout
Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called…
STAT+: Cue Health, Covid-19 testing company, is shutting down
In an abrupt change of course from plans earlier in the month, at-home test maker…
STAT+: New antiviral works against coronaviruses in mice, but human testing will have to wait
During the Covid-19 pandemic, vaccines were the main line of defense. Startlingly effective shots quickly…
STAT+: Eyeing GLP-1 opportunity, Click buys assets of Better Therapeutics
Digital therapeutics company Click Therapeutics announced Wednesday it will acquire the assets of Better Therapeutics,…
STAT+: Pharmalittle: We’re watching a ban compounded versions of GLP-1s, a Biogen acquisition, and more
Good morning from San Diego. This is Jonathan Wosen, West Coast biotech and life sciences…
STAT+: Biogen joins immunology wave with $1.15 billion acquisition
Biogen is joining the industry’s fervor over immune and inflammatory disease drug development with a…
STAT+: Pharmalittle: We’re watching BIO layoffs, AstraZeneca plans to double revenue, and more
Good morning from the Pharmalittle campus, where I’m filling in for Ed. Normally, I’m the…
STAT+: At a flashy new research hub, AstraZeneca lays out ambitious growth goals
CAMBRIDGE, England — On a bit of a roll, AstraZeneca on Tuesday laid out ambitious…
STAT+: AltruBio raises $225 million to develop ulcerative colitis drug and other immune checkpoint enhancers
Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have…
STAT+: GSK’s asthma push continues as drug succeeds in Phase 3 trials
A new asthma treatment that could be administered just once every six months has succeeded…
STAT+: PBM executives invited to testify before House panel
WASHINGTON — Executives from the three major pharmacy benefit manager companies have been invited to…
STAT+: AI & drug discovery: A biotech CEO, a scientist, and a venture capitalist separate hype from reality
Artificial intelligence is a rapidly improving technology. But its progress in drug development faces an…
STAT+: BIO to announce reorganization, senior leaders expected to depart
WASHINGTON — The Biotechnology Innovation Organization on Monday is announcing a significant restructuring accompanied by…
STAT+: A novel spinal cord stimulator treats paralysis without surgery. FDA will rule on it soon
After his spinal cord injury in 2014, Sherown Campbell worked hard to regain as much…
STAT+: Class action against UnitedHealth asks about DOJ probe transparency
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
STAT+: Pharmalittle: We’re reading about Sanders’ pharma pressure campaign, AstraZeneca’s new ADC factory, and more
Good morning from STAT reporter Andrew Joseph, filling in here for Mr. Pharmalot. We’ve recently…
STAT+: Private equity escapes FTC in court, but anesthesia group doesn’t
Welsh, Carson, Anderson & Stowe has wiggled out of the grasp of the Federal Trade…
STAT+: Medical crowdfunding isn’t a solution for skyrocketing health care costs
In the United States, health care costs are so out of control that medical crowdfunding…
STAT+: Why health systems are faring better so far in 2024
Americans, especially Medicare beneficiaries, are getting more medical care these days. Demand from aging Baby…
STAT+: ChatGPT for genomes: introducing a CRISPR-designing generative AI
In 2018, during her chemistry Nobel Prize lecture, Frances Arnold noted that scientists had arrived…
.jpg)
STAT+: Venture capitalist Bob Kocher on generative AI startups, Change Healthcare cyberattack
SAN FRANCISCO — Health tech investor Bob Kocher has seen some bad AI-related startup pitches…
STAT+: Wearable devices generate powerful data but it’s not useful to doctors, yet
Just because the Food and Drug Administration has given the Apple Watch and other wearable…
STAT+: Amid acquisition speculation, Cytokinetics CEO stresses company can launch heart drug on its own
As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage…
STAT+: Pharmalittle: We’re reading about an Amgen drug for lung cancer, a Novo plant fire, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Data integrity watchdogs call for stronger safeguards in scientific journals
SAN FRANCISCO — According to Elisabeth Bik, a scientific watchdog who has discovered thousands of…
STAT+: To bolster global health, Wellcome Trust’s new CEO thinks Big Tech should get involved
LONDON — The key groups involved in addressing global health problems often include governments, foundations,…
STAT+: NVIDIA’s Kimberly Powell touts progress on AI in drug discovery
SAN FRANCISCO — In the world of drug discovery, AI progress is often measured by…
STAT+: Microsoft’s Peter Lee says ChatGPT shouldn’t be used for initial diagnosis
SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is…
STAT+: Analysis of pharmaceutical R&D ranks Novo Nordisk and Johnson & Johnson above their peers
When it comes to bringing an experimental drug to market and selling it, Novo Nordisk,…
STAT+: PDS Biotech’s survival benefit is absurdly overstated
This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers…